ABSTRACT
Nicotine intake by cigarettes is linked to the maintenance and development of anxiety disorders and impairs adaptive discrimination of threat and safety in humans. Yet, it is unclear if nicotine exerts a causal pharmacological effect on the affective and neural mechanisms that underlie aversive learning. We conducted a pre-registered, pseudo-randomly and double-blinded pharmacological fMRI study to investigate the effect of acute nicotine on Fear Acquisition and Extinction in non-smokers (n=88). Our results show that nicotine administration led to decreased discrimination between threat and safety in subjective fear. Nicotine furthermore decreased differential (threat vs. safety) activation in the hippocampus, which was functionally coupled with Nucleus Accumbens and amygdala, compared to placebo controls. Additionally, nicotine led to overactivation of the ventral tegmental area. This study provides mechanistic evidence that single doses of nicotine impair neural substrates of adaptive aversive learning in line with the risk for the development of pathological anxiety.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
DRKS00025233 (German Clinical Trials Register: https: drks.de/search/en/trial/DRKS00025233)
Funding Statement
This work was supported by the German Research Foundation (DFG) by an individual research Grant 7470/3-1 awarded to Jan Haaker, and the SFB 936 (178316478 - C06) and the TRR 289 (422744262 - A06) awarded to Jonas Rauh.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the ethics committee "Ethikkommission der Aerztekammer Hamburg" (processing number: PV5514).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Additional details on data analysis procedure and unconditioned stimulus in method section of main manuscript. Figures on paradigm, fear rating and hippocampal activity revised for clarification.
Data Availability
The rating and SCR data, as well as the contrast fMR images used in this study are available for download.
https://gin.g-node.org/MadeleineMueller/Mueller_et_al_2023_Nicotine_and_fear
